ArticleVirusdisease2025
Seroprevalence study of the new coronavirus (SARS-CoV-2) in families and cohabitants of confirmed cases in Mashhad, Iran: a cross-sectional study.
Article in Virusdisease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The seroepidemiological characteristics of the SARS-CoV-2 were investigated along with the secondary infection rate in the household of confirmed patients in a high-risk population in Mashhad, Iran. The current descriptive cross-sectional study includes a total of 154 confirmed cases of SARS-CoV-2 infection in Mashhad, Iran, from March 2021 to December 2021. The participants' families were screened for SARS-CoV-2 secondary infection rate, and a standard checklist containing the research parameters was completed by all participants. The participants' average age was 43.19 ± 9.86 years, of which 80 (51.9%) were female and the rest were male. Of the participants, 147 (95.5%) reported using face masks, and 83 (53.9%) were using masks all the time. IgG and IgM of COVID-19 were positive in 43 (27.9%) and 8 (5.2%) individuals, respectively. The average positive rate in the participants was 0.12 ± 0.24. Wearing masks when contracting with an infected patient ( Supplementary Information: The online version contains supplementary material available at 10.1007/s13337-024-00903-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.